ROXBORO, N.C., Oct. 12, 2022 Open Book Extracts (OBX), an ingredient manufacturer and product development completed its first cosmetic research study, an open-label, randomized, passive-control study examining the impact of topical serums containing Tetrahydrocannabivarin (THCV) on skin acne.
Building on literature outlining THCV’s anti-inflammatory topical properties, OBX conducted the study to explore THCV’s therapeutic potential to improve skin acne.
In the study, healthy male and female subjects with Fitzpatrick skin types I-VI with mild to moderate acne on the face were studied under a blinded, randomized, vehicle controlled 4-week study evaluating the efficacy of several topical cannabinoid formulations including THCV for the treatment of facial acne. OBX was intentional about the inclusion of a diversity of skin tones in the study, in order to understand potential benefits for the products of interest across all skin types.
The study was conducted in collaboration with an industry leading dermatologist, Dr. Jeffrey Dover, and research dermatologist, Dr. Zoe Draelos. This is one of the first clinical evaluations of THCV in a topical preparation–there were no tolerability issues and promising efficacy results that will inform the design of future clinical trials.
(This information is primarily sourced from Open Book Extracts. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).